Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revance to Participate in Upcoming Investor Conferences By: Revance Therapeutics, Inc. via Business Wire March 07, 2023 at 08:00 AM EST Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences. Barclays Global Healthcare Conference Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Tuesday, March 14, at 9:00 A.M. ET, in Miami, Florida. Guggenheim Healthy Altitudes Summit Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Thursday, March 16, at 7:45 A.M. MT, in Telluride, Colorado. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity. Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn. “Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005508/en/Contacts Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 sfahy@revance.com Investors Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 laurence@gilmartinir.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Revance to Participate in Upcoming Investor Conferences By: Revance Therapeutics, Inc. via Business Wire March 07, 2023 at 08:00 AM EST Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences. Barclays Global Healthcare Conference Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Tuesday, March 14, at 9:00 A.M. ET, in Miami, Florida. Guggenheim Healthy Altitudes Summit Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Thursday, March 16, at 7:45 A.M. MT, in Telluride, Colorado. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity. Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn. “Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005508/en/Contacts Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 sfahy@revance.com Investors Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences. Barclays Global Healthcare Conference Chief Executive Officer, Mark J. Foley, is scheduled to participate in a fireside chat on Tuesday, March 14, at 9:00 A.M. ET, in Miami, Florida. Guggenheim Healthy Altitudes Summit Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Thursday, March 16, at 7:45 A.M. MT, in Telluride, Colorado. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About Revance Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity. Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn. “Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005508/en/
Media Revance Therapeutics, Inc.: Sara Fahy, 949-887-4476 sfahy@revance.com Investors Revance Therapeutics, Inc.: Jessica Serra, 510-279-6886 jessica.serra@revance.com or Gilmartin Group, LLC.: Laurence Watts, 619-916-7620 laurence@gilmartinir.com
